Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

May 5-7, 2016
Zagreb, Croatia

Continuing Education

ACCME Accreditation

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This live educational activities are designed to meet the educational needs of European hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) who are involved and/or interested in the treatment of patients with MPN and MDS.

Objectives

After successful completion of this activity, participants should be able to:

      • Evaluate molecular and genetic abnormalities, their role in pathology of disease, and how they can potentially be utilized to enhance diagnostic, prognostic, and therapeutic strategies to enhance outcomes in patients with MPN or MDS
      • Assess finalized and ongoing clinical trial data utilizing standard of care and/or investigational therapies for the optimal treatment and management of patients with MPN or MDS 
      • Recognize disease- and therapy-associated adverse events and formulate strategies for their management 
      • Assess strategies for the management of MPN or MDS patients who are intolerant or develop resistance to therapy
      • Formulate optimal evidence-based strategies for the management of patients with MPN or MDS that take into consideration disease stage, cytogenetic analysis, and patient risk factors